Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats
Treatment of status epilepticus, a life-threatening condition of prolonged seizures, becomes less effective when treatment is delayed. This study used a preclinical rat model of chemical-induced seizure to evaluate the ability of the antiseizure medication perampanel as a second-line therapy to midazolam in the treatment of status epilepticus. We show that perampanel following midazolam treatment improved seizure outcomes and reduced brain damage caused by status epilepticus, compared to midazolam alone.
Authors
- Michael F. Stone
- Jérôme Niquet (ORCID: https://orcid.org/0000-0002-1005-0517)
- Donna A. Nguyen
- Marcio de Araujo Furtado
- Claude G. Wasterlain (ORCID: https://orcid.org/0000-0002-2100-9114)
- Lucille A. Lumley (ORCID: https://orcid.org/0000-0003-4162-8817)
- Caroline R. Schultz (ORCID: https://orcid.org/0000-0003-3169-7317)
- Abiel K. Biney
- Hailey G. Steier
Institutions
- University of California, Los Angeles (US)
- United States Army (US)
- VA Greater Los Angeles Healthcare System (US)
Publication Details
- Journal
- Epilepsia Open
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1002/epi4.70083
- Citations
- 1
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- U.S. Department of Defense
- U.S. Department of Energy
- Oak Ridge Associated Universities
- National Institutes of Health
- Oak Ridge Institute for Science and Education
- NIH Office of the Director
- National Institute of Allergy and Infectious Diseases
- U.S. Army Medical Research Institute of Chemical Defense